A new live respiratory syncytial virus (RSV) vaccine holds promise against the infection, suggests a recent trial.
- RSV seronegative children between 6 and 24 months of age were given either intranasal doses of a placebo of RSV cold-passage/stabilized 2 (RSVcps2) vaccine, a previously studied product that was altered with mutations to stabilize it against diattenuation.
- 85% of the children were RSVcps2, 77% shed vaccine virus, and 59% developed at least a 4-fold increase in neutralizing antibody titers.
- Placebo and vaccine recipients both experienced a 50% rate of respiratory tract, febrile illness, or both.
Buchholz UJ, Cunningham CK, Muresan P, et al. Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children. [Published online ahead of print March 2, 2018]. J Infect Dis. doi:10.1093/infdis/jiy066.
This Week's Must Reads
Antibiotic Use Among US Older Adults, BMJ; ePub 2018 Jul 27; Olesen, Barnett, et al
Healthy Behaviors & Reduced Risk of Obesity , Mayo Clin Proc; ePub 2018 Jul 27; Shook, et al
Modifiable Risk Factors in New BP Categories, Am J Med; ePub 2018 Jul 26; Gu, Yue, et al
Psychological Screening for Youth with Abdominal Pain, Pediatrics; ePub 2018 Jul 25; Cunningham, et al
Low-Calorie Sweetened Beverages & Cardiometabolic Health, Circulation; ePub 2018 Jul 30; Johnson, et al
Must Reads in Vaccines
AAP Revision on Dismissing Vaccine-Refusing Families, JAMA Pediatr; ePub 2018 Apr 30; Deem, et al
Creating Preventive Vaccines for Lynch Syndrome, JAMA Oncology; ePub 2018 Apr 16; Chang, et al
Children with Autism Less Likely to Be Vaccinated, JAMA Pediatr; ePub 2018 Mar 26; Zerbo, et al
Antibody-Based Vaccines & Intracellular Pathogens, Curr Opin Immunol; ePub 2018 Apr 25; Casadevall
Designing an Effective Hepatitis C Vaccine, Trends Microbiol; ePub 2018 Apr 24; Kinchen, et al